Some experts are seriously wary of AI in healthcare

A Harvard Law School professor is warning that AI may be hazardous to the health of U.S. healthcare.

“I think of machine learning kind of as asbestos,” Jonathan Zittrain, JD, MPA, said in a presentation at Harvard Medical School Tuesday. “It turns out that it’s all over the place, even though at no point did you explicitly install it, and it has possibly some latent bad effects that you might regret later, after it’s already too hard to get it all out.”

According to coverage of the event by Stat News, Zittrain was in good company. Speakers raised red flags over nettlesome issues—ethical, political and scientific—that have been barely addressed to date.

One expert noted that data from wearables cannot be fully anonymized. Another said bias is baked into every algorithm.

“Using AI has the potential to advance medical insights through the collection and analysis of large volumes and types of health data,” said Kadija Ferryman, a fellow at the Data & Society Research Institute in New York. “However, we must keep our focus on the potential for these technologies to exacerbate and extend unfair outcomes.”

Read the rest of Stat’s coverage:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.